A Prospective, Randomized, Placebo-Controlled Study of a Combination of Simvastatin and Chemotherapy in Metastatic Breast Cancer

Table 4

Factors associated with overall survival for total cohort.

Variables	Univariate analysis		Multivariate analysis
	Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
hsCRP (mg/l)
>10 vs. ≤ 10	2.210 (1.339–3.647)	0.002	2.168 (1.299–3.616)	0.003
LDH (U/l)
>480 vs. ≤ 480	2.335 (1.351–4.036)	0.002	2.213 (1.273–3.845)	0.005
CEA (ng/ml)
>5 vs. ≤ 5	1.842 (1.119–3.033)	0.016
CA15-3 (U/ml)
>30 vs. ≤ 30	1.289 (0.673–2.469)	0.444
Age (years)
≥50 vs. <50	0.555 (0.330–0.932)	0.026
ECOG-PS
1/2 vs. 0	2.352 (0.939–5.893)	0.068
HER2
(−) vs. (+)	1.009 (0.583–1.747)	0.973
Hormone receptors (HRs)
(−) vs. (+)	0.681 (0.412–1.124)	0.133
No. of metastatic sites
≥2 sites vs. 1 site	1.802 (1.095–2.965)	0.020
Chemotherapy line
≥2^nd line vs. 1^st line	1.692 (1.025–2.795)	0.040	1.766 (1.067–2.923)	0.027